Lay Title: A Study Using the Study Drug CPI-1205 with Enzalutamide or Abiraterone and Prednisone to Treat Your Prostate Cancer
Technical Title: ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration
Resistant Prostate Cancer
Disease Type: Metastatic, castration-resistant prostate cancer
Basic information: The purpose of this study is to evaluate the effectiveness of CPI-1205, the study drug, in combination with enzalutamide or abiraterone/prednisone (which are standard treatments for mCRPC) compared to enzalutamide or abiraterone/prednisone alone.
CPI-1205 is a drug that is taken by mouth two to three times per day. It is a small molecule inhibitor of an enzyme called Enhancer of Zeste Homolog 2 (EZH2), which has been shown to play a role in the development of prostate cancer. CPI-1205 is thought to work by blocking EZH2 activity.
Research Procedures (not a complete list):
Once you start treatment, you will come to the clinic at least twice during the first cycle (28 days), at least two to three times during the second cycle, and once per cycle thereafter. You will complete a physical exam, blood tests, and questionnaires during these visits. Some visits may require additional tests. During the first two cycles, you may have visits that are over 6 hours long in order to collect research blood samples.
Eligibility Criteria (not a complete list):
For More Detailed Information, Contact:
Matthew Rettig, MD, Principal Investigator
Ankush Sachdeva, Study Coordinator, (310) 794-3421